Cargando…

438. Dalbavancin Clinical Experience at an NCI Designated Cancer Center

BACKGROUND: Dalbavancin (DAL) is a long-acting lipoglycopeptide, which allows for up to 2 weeks of therapy from a single dose. Outside of its FDA-approved indication for the treatment of acute bacterial skin and skin structure infections (ABSSSI), there is a growing interest in the utilization of DA...

Descripción completa

Detalles Bibliográficos
Autores principales: McDaneld, Patrick, Smith, Devlin, Tverdek, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810544/
http://dx.doi.org/10.1093/ofid/ofz360.511